Fund Trust Ii Marshman Net Worth

The estimated Net Worth of Fund Trust Ii Marshman is at least $397 Million dollars as of 21 August 2020. Fund Marshman owns over 339,476 units of Harmony Biosciences stock worth over $397,073,754 and over the last 4 years Fund sold HRMY stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fund Marshman HRMY stock SEC Form 4 insiders trading

Fund has made over 1 trades of the Harmony Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Fund bought 339,476 units of HRMY stock worth $8,147,424 on 21 August 2020.

The largest trade Fund's ever made was buying 339,476 units of Harmony Biosciences stock on 21 August 2020 worth over $8,147,424. On average, Fund trades about 169,738 units every 0 days since 2020. As of 21 August 2020 Fund still owns at least 10,651,120 units of Harmony Biosciences stock.

You can see the complete history of Fund Marshman stock trades at the bottom of the page.

What's Fund Marshman's mailing address?

Fund's mailing address filed with the SEC is 330 N. WABASH AVE, SUITE 300, , CHICAGO, IL, 60611.

Insiders trading at Harmony Biosciences

Over the last 4 years, insiders at Harmony Biosciences have traded over $224,163,932 worth of Harmony Biosciences stock and bought 514,681 units worth $12,537,009 . The most active insiders traders include Holdings A/S Novo, Andreas Wicki und Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of $2,907,691. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth $559,200.

What does Harmony Biosciences do?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Complete history of Fund Marshman stock trades at Harmony Biosciences

Harmony Biosciences executives and stock owners

Harmony Biosciences executives and other stock owners filed with the SEC include:

• John Charles Jacobs M.B.A.,
  Pres, CEO & Director
• Dr. Jeffrey M. Dayno M.D.,
  Chief Medical Officer
• Jeffrey Dierks M.B.A.,
  Exec. VP & Chief Commercial Officer
• Andrew Serafin J.D., M.B.A.,
  Exec. VP & Chief Strategy Officer
• Jeffrey S. Aronin,
  Founder & Non-Exec. Chairman
• Patricia L. Bank,
  Investor Relations Officer
• Nancy Leone,
  Head of Corp. Communications
• Tricia Glover,
  Chief Compliance Officer
• Christian Ulrich,
  Gen. Counsel
• Sharon Goldbach,
  Head of Facilities Operations & Exec. Admin.
• David Bradshaw,
  Head of Technical Operations
• Sandip S. Kapadia CPA, M.B.A.,
  Chief Financial Officer
• Holdings A/S Novo,
  10% owner
• Iv Pharma Holdings, Llc Val...,
  
• Fund Trust Ii Marshman,
  10% owner
• Andrew Serafin,
  CHIEF STRATEGY OFFICER
• Linda M Szyper,
  
• Antonio J. Gracias,
  
• R. Mark Graf,
  
• Eric L Motley,
  Director
• Jeffrey S Aronin,
  Director
• Jeffrey Dierks,
  CHIEF COMMERCIAL OFFICER
• John C Jacobs,
  PRESIDENT, CEO
• Jack Nielsen,
  
• Sandip Kapadia,
  CHIEF FINANCIAL OFFICER
• Jeffrey M. Dayno,
  PRESIDENT, CEO
• Gary Sender,
  
• Juan A. Sabater,
  
• Peter Anastasiou,
  
• Kumar Budur,
  CHIEF MEDICAL OFFICER